Scarica l'app Stockscreener
877.62
3.50%
-31.87
Dopo l'orario di chiusura:
875.00
-2.62
-0.30%
Precedente Chiudi:
$909.49
Aprire:
$904.79
Volume 24 ore:
325.04K
Relative Volume:
0.96
Capitalizzazione di mercato:
$54.58B
Reddito:
$4.16B
Utile/perdita netta:
$1.29B
Rapporto P/E:
44.81
EPS:
19.5837
Flusso di cassa netto:
$734.26M
1 W Prestazione:
-6.60%
1M Prestazione:
+1.79%
6M Prestazione:
+11.30%
1 anno Prestazione:
+55.80%
Intervallo 1D:
$868.54
$904.79
Intervallo di 1 settimana:
$868.54
$940.25
Portata 52W:
$553.54
$953.58
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-12-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Ripresa | Truist | Buy |
| 2025-09-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-05-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Strong Buy |
| 2024-10-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-24 | Downgrade | UBS | Buy → Neutral |
| 2023-07-17 | Ripresa | Evercore ISI | Outperform |
| 2023-06-15 | Iniziato | Societe Generale | Sell |
| 2023-05-31 | Iniziato | UBS | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Iniziato | William Blair | Outperform |
| 2022-10-12 | Iniziato | Oppenheimer | Perform |
| 2022-07-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Ripresa | Stifel | Buy |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-23 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Iniziato | Deutsche Bank | Hold |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-18 | Iniziato | UBS | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Iniziato | Redburn | Neutral |
| 2021-03-05 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Iniziato | H.C. Wainwright | Neutral |
| 2020-02-10 | Iniziato | BofA/Merrill | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-10-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Iniziato | JP Morgan | Overweight |
| 2019-09-27 | Iniziato | Wells Fargo | Market Perform |
| 2019-09-16 | Ripresa | Cowen | Outperform |
| 2019-06-28 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-18 | Ripresa | SunTrust | Buy |
| 2019-01-04 | Iniziato | Morgan Stanley | Overweight |
| 2018-12-17 | Iniziato | Goldman | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-06-29 | Iniziato | Nomura | Buy |
| 2018-04-09 | Iniziato | SunTrust | Buy |
| 2018-01-29 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Argen X Se Adr Borsa (ARGX) Ultime notizie
VCRE|Vicore Pharma Holding AB ADR|Price:13.780|Chg%:-0.135 - TradingKey
RBC Capital Adjusts argenx SE ADR Price Target to $945 From $890, Maintains Outperform Rating - marketscreener.com
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point - Investor's Business Daily
Argenx, stock of the day, eyes buy point amid triple-digit growth - MSN
Argenx Fends Off First-Quarter Seasonality, But Shares Defy Analysts' Bullish Views - Investor's Business Daily
Argenx stock holds the focus on its global immunology franchise. - ad-hoc-news.de
Vicore Pharma Holding AB ADR (VCRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ARGXArgen X SE ADR Options - Finviz
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx stock hits all-time high at 934.69 USD - Investing.com
ARGX Stock Price, Quote & Chart - ChartMill
BofA raises argenx stock price target to $1,088 on myositis data - Investing.com South Africa
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth - Investor's Business Daily
A2H9WD Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
argenx SE Sponsored ADR Actuals & Estimates (NASDAQ:ARGX) - TradingView
H.C. Wainwright reiterates argenx stock rating on myositis trial update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates argenx stock rating on myositis trial update - Investing.com
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy? - Investor's Business Daily
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity By Investing.com - Investing.com South Africa
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data By Investing.com - Investing.com Australia
Argenx stock price target held at $1,014 by Oppenheimer on myositis strategy - Investing.com Nigeria
Argenx stock falls after myositis drug trial update - Investing.com
Biotech breakout: iShares Biotechnology ETF hits all-time high - MSN
Form 6K argenx NV ADR For: 23 June - Investing.com UK
Form 6K argenx NV ADR For: 23 June By Investing.com - Investing.com Nigeria
argenx to Host Autoimmune Myositis R&D Webinar - GlobeNewswire Inc.
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Argenx SE Stock (NL0010832176): Analyst price target move puts biotech in focus - AD HOC NEWS
European ADRs Rose In US Trading As Biotech Led - Finimize
European Equities Traded in US as ADRs Rise in Thursday Trading - Moomoo
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know - TradingView
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
William O'Neil Initiates Argenx at Buy - Moomoo
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference - Barchart.com
Argen X Se Adr Azioni (ARGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):